These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8930129)

  • 1. Effects of cytosine arabinoside on human leukemia cells.
    Crisp LB; Smith SM; Mathers MA; Young GA; Lyons SD; Christopherson RI
    Int J Biochem Cell Biol; 1996 Sep; 28(9):1061-9. PubMed ID: 8930129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.
    Wang LM; White JC; Capizzi RL
    Cancer Chemother Pharmacol; 1990; 25(6):418-24. PubMed ID: 2311169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibition of human leukemia cell growth by deoxyguanosine and 1-beta-D-arabinofuranosylcytosine.
    Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
    Biochem Pharmacol; 1984 Apr; 33(7):1059-63. PubMed ID: 6712715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
    Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
    Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.
    Catapano CV; Chandler KB; Fernandes DJ
    Cancer Res; 1991 Apr; 51(7):1829-35. PubMed ID: 1706219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular dCTP/ara-CTP ratio and the cytotoxic effect of ara-C.
    Kawasaki H; Kuwabara H; Hori H; Higashigawa M; Ohkubo T; Sakurai M
    Cancer Invest; 1991; 9(4):409-13. PubMed ID: 1884247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of cytosine arabinoside-5'-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity.
    Köhl U; Schwabe D; Montag E; Bauer S; Mieth B; Cinatl J; Cinatl J; Rohrbach E; Mainke M; Weissflog A
    Eur J Cancer; 1995; 31A(2):209-14. PubMed ID: 7718327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methotrexate and 1-beta-D-arabinofuranosylcytosine on pools of deoxyribonucleoside triphosphates in L1210 ascites cells.
    Roberts D; Peck C
    Cancer Res; 1981 Feb; 41(2):505-10. PubMed ID: 7448798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
    Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
    Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
    Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the interaction between cytosine arabinoside and etoposide in vivo and in vitro.
    Liliemark J; Knochenhauer E; Gruber A; Pettersson B; Björkholm M; Peterson C
    Eur J Haematol; 1993 Jan; 50(1):22-5. PubMed ID: 8436210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical modulation of cytarabine triphosphate by clofarabine.
    Cooper T; Ayres M; Nowak B; Gandhi V
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):361-368. PubMed ID: 15723262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
    Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
    Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I; Saito S; Hori K; Suzuki M; Sato H
    Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.